Cargando…
A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials
The Hippo pathway is involved in colorectal cancer (CRC) development and progression. The Hippo regulator Rassf1a is also involved in the Ras signaling cascade. In this work, we tested single nucleotide polymorphisms within Hippo components and their association with outcome in CRC patients treated...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378677/ https://www.ncbi.nlm.nih.gov/pubmed/27698403 http://dx.doi.org/10.1038/tpj.2016.69 |
_version_ | 1782519460141203456 |
---|---|
author | Sebio, A. Stintzing, S. Heinemann, V. Sunakawa, Y. Zhang, W. Ichikawa, W. Tsuji, A. Takahashi, T. Parek, A. Yang, D. Cao, S. Ning, Y. Stremitzer, S. Matsusaka, S. Okazaki, S. Barzi, A. Berger, M. Lenz, H-J |
author_facet | Sebio, A. Stintzing, S. Heinemann, V. Sunakawa, Y. Zhang, W. Ichikawa, W. Tsuji, A. Takahashi, T. Parek, A. Yang, D. Cao, S. Ning, Y. Stremitzer, S. Matsusaka, S. Okazaki, S. Barzi, A. Berger, M. Lenz, H-J |
author_sort | Sebio, A. |
collection | PubMed |
description | The Hippo pathway is involved in colorectal cancer (CRC) development and progression. The Hippo regulator Rassf1a is also involved in the Ras signaling cascade. In this work, we tested single nucleotide polymorphisms within Hippo components and their association with outcome in CRC patients treated with cetuximab. Two cohorts treated with cetuximab plus chemotherapy were evaluated (198 RAS wild-type (wt) patients treated with first-line FOLFIRI plus Cetuximab within the FIRE-3 trial and 67 Ras wt patients treated either with first-line mFOLFOX6 or SOX plus Cetuximab). In these two populations, Rassf1a rs2236947 was associated with overall survival, as patients with a CC genotype had significantly longer OS compared to those with CA or AA genotypes. This association was stronger in patients with left-side CRC [HR: 1.79 (1.01–3.14); P=0.044 and HR: 2.83 (1.14–7.03); P=0.025, for Fire 3 and JACCRO cohorts, respectively]. Rassf1a rs2236947 is a promising biomarker for patients treated with cetuximab plus chemotherapy. |
format | Online Article Text |
id | pubmed-5378677 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
record_format | MEDLINE/PubMed |
spelling | pubmed-53786772017-04-04 A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials Sebio, A. Stintzing, S. Heinemann, V. Sunakawa, Y. Zhang, W. Ichikawa, W. Tsuji, A. Takahashi, T. Parek, A. Yang, D. Cao, S. Ning, Y. Stremitzer, S. Matsusaka, S. Okazaki, S. Barzi, A. Berger, M. Lenz, H-J Pharmacogenomics J Article The Hippo pathway is involved in colorectal cancer (CRC) development and progression. The Hippo regulator Rassf1a is also involved in the Ras signaling cascade. In this work, we tested single nucleotide polymorphisms within Hippo components and their association with outcome in CRC patients treated with cetuximab. Two cohorts treated with cetuximab plus chemotherapy were evaluated (198 RAS wild-type (wt) patients treated with first-line FOLFIRI plus Cetuximab within the FIRE-3 trial and 67 Ras wt patients treated either with first-line mFOLFOX6 or SOX plus Cetuximab). In these two populations, Rassf1a rs2236947 was associated with overall survival, as patients with a CC genotype had significantly longer OS compared to those with CA or AA genotypes. This association was stronger in patients with left-side CRC [HR: 1.79 (1.01–3.14); P=0.044 and HR: 2.83 (1.14–7.03); P=0.025, for Fire 3 and JACCRO cohorts, respectively]. Rassf1a rs2236947 is a promising biomarker for patients treated with cetuximab plus chemotherapy. 2016-10-04 2018-01 /pmc/articles/PMC5378677/ /pubmed/27698403 http://dx.doi.org/10.1038/tpj.2016.69 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Sebio, A. Stintzing, S. Heinemann, V. Sunakawa, Y. Zhang, W. Ichikawa, W. Tsuji, A. Takahashi, T. Parek, A. Yang, D. Cao, S. Ning, Y. Stremitzer, S. Matsusaka, S. Okazaki, S. Barzi, A. Berger, M. Lenz, H-J A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials |
title | A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials |
title_full | A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials |
title_fullStr | A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials |
title_full_unstemmed | A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials |
title_short | A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials |
title_sort | genetic variant in rassf1a predicts outcome in mcrc patients treated with cetuximab plus chemotherapy: results from fire-3 and jaccro 05 and 06 trials |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378677/ https://www.ncbi.nlm.nih.gov/pubmed/27698403 http://dx.doi.org/10.1038/tpj.2016.69 |
work_keys_str_mv | AT sebioa ageneticvariantinrassf1apredictsoutcomeinmcrcpatientstreatedwithcetuximabpluschemotherapyresultsfromfire3andjaccro05and06trials AT stintzings ageneticvariantinrassf1apredictsoutcomeinmcrcpatientstreatedwithcetuximabpluschemotherapyresultsfromfire3andjaccro05and06trials AT heinemannv ageneticvariantinrassf1apredictsoutcomeinmcrcpatientstreatedwithcetuximabpluschemotherapyresultsfromfire3andjaccro05and06trials AT sunakaway ageneticvariantinrassf1apredictsoutcomeinmcrcpatientstreatedwithcetuximabpluschemotherapyresultsfromfire3andjaccro05and06trials AT zhangw ageneticvariantinrassf1apredictsoutcomeinmcrcpatientstreatedwithcetuximabpluschemotherapyresultsfromfire3andjaccro05and06trials AT ichikawaw ageneticvariantinrassf1apredictsoutcomeinmcrcpatientstreatedwithcetuximabpluschemotherapyresultsfromfire3andjaccro05and06trials AT tsujia ageneticvariantinrassf1apredictsoutcomeinmcrcpatientstreatedwithcetuximabpluschemotherapyresultsfromfire3andjaccro05and06trials AT takahashit ageneticvariantinrassf1apredictsoutcomeinmcrcpatientstreatedwithcetuximabpluschemotherapyresultsfromfire3andjaccro05and06trials AT pareka ageneticvariantinrassf1apredictsoutcomeinmcrcpatientstreatedwithcetuximabpluschemotherapyresultsfromfire3andjaccro05and06trials AT yangd ageneticvariantinrassf1apredictsoutcomeinmcrcpatientstreatedwithcetuximabpluschemotherapyresultsfromfire3andjaccro05and06trials AT caos ageneticvariantinrassf1apredictsoutcomeinmcrcpatientstreatedwithcetuximabpluschemotherapyresultsfromfire3andjaccro05and06trials AT ningy ageneticvariantinrassf1apredictsoutcomeinmcrcpatientstreatedwithcetuximabpluschemotherapyresultsfromfire3andjaccro05and06trials AT stremitzers ageneticvariantinrassf1apredictsoutcomeinmcrcpatientstreatedwithcetuximabpluschemotherapyresultsfromfire3andjaccro05and06trials AT matsusakas ageneticvariantinrassf1apredictsoutcomeinmcrcpatientstreatedwithcetuximabpluschemotherapyresultsfromfire3andjaccro05and06trials AT okazakis ageneticvariantinrassf1apredictsoutcomeinmcrcpatientstreatedwithcetuximabpluschemotherapyresultsfromfire3andjaccro05and06trials AT barzia ageneticvariantinrassf1apredictsoutcomeinmcrcpatientstreatedwithcetuximabpluschemotherapyresultsfromfire3andjaccro05and06trials AT bergerm ageneticvariantinrassf1apredictsoutcomeinmcrcpatientstreatedwithcetuximabpluschemotherapyresultsfromfire3andjaccro05and06trials AT lenzhj ageneticvariantinrassf1apredictsoutcomeinmcrcpatientstreatedwithcetuximabpluschemotherapyresultsfromfire3andjaccro05and06trials AT sebioa geneticvariantinrassf1apredictsoutcomeinmcrcpatientstreatedwithcetuximabpluschemotherapyresultsfromfire3andjaccro05and06trials AT stintzings geneticvariantinrassf1apredictsoutcomeinmcrcpatientstreatedwithcetuximabpluschemotherapyresultsfromfire3andjaccro05and06trials AT heinemannv geneticvariantinrassf1apredictsoutcomeinmcrcpatientstreatedwithcetuximabpluschemotherapyresultsfromfire3andjaccro05and06trials AT sunakaway geneticvariantinrassf1apredictsoutcomeinmcrcpatientstreatedwithcetuximabpluschemotherapyresultsfromfire3andjaccro05and06trials AT zhangw geneticvariantinrassf1apredictsoutcomeinmcrcpatientstreatedwithcetuximabpluschemotherapyresultsfromfire3andjaccro05and06trials AT ichikawaw geneticvariantinrassf1apredictsoutcomeinmcrcpatientstreatedwithcetuximabpluschemotherapyresultsfromfire3andjaccro05and06trials AT tsujia geneticvariantinrassf1apredictsoutcomeinmcrcpatientstreatedwithcetuximabpluschemotherapyresultsfromfire3andjaccro05and06trials AT takahashit geneticvariantinrassf1apredictsoutcomeinmcrcpatientstreatedwithcetuximabpluschemotherapyresultsfromfire3andjaccro05and06trials AT pareka geneticvariantinrassf1apredictsoutcomeinmcrcpatientstreatedwithcetuximabpluschemotherapyresultsfromfire3andjaccro05and06trials AT yangd geneticvariantinrassf1apredictsoutcomeinmcrcpatientstreatedwithcetuximabpluschemotherapyresultsfromfire3andjaccro05and06trials AT caos geneticvariantinrassf1apredictsoutcomeinmcrcpatientstreatedwithcetuximabpluschemotherapyresultsfromfire3andjaccro05and06trials AT ningy geneticvariantinrassf1apredictsoutcomeinmcrcpatientstreatedwithcetuximabpluschemotherapyresultsfromfire3andjaccro05and06trials AT stremitzers geneticvariantinrassf1apredictsoutcomeinmcrcpatientstreatedwithcetuximabpluschemotherapyresultsfromfire3andjaccro05and06trials AT matsusakas geneticvariantinrassf1apredictsoutcomeinmcrcpatientstreatedwithcetuximabpluschemotherapyresultsfromfire3andjaccro05and06trials AT okazakis geneticvariantinrassf1apredictsoutcomeinmcrcpatientstreatedwithcetuximabpluschemotherapyresultsfromfire3andjaccro05and06trials AT barzia geneticvariantinrassf1apredictsoutcomeinmcrcpatientstreatedwithcetuximabpluschemotherapyresultsfromfire3andjaccro05and06trials AT bergerm geneticvariantinrassf1apredictsoutcomeinmcrcpatientstreatedwithcetuximabpluschemotherapyresultsfromfire3andjaccro05and06trials AT lenzhj geneticvariantinrassf1apredictsoutcomeinmcrcpatientstreatedwithcetuximabpluschemotherapyresultsfromfire3andjaccro05and06trials |